NEW YORK (GenomeWeb News) - Shares in Stratagene were down approximately 6 percent, or $.43, at $6.41 in mid-afternoon trading today after the company said that litigation-related charges swung second-quarter earnings to a loss.
As GenomeWeb News reported this morning, Stratagene said total revenues were down 6 percent to $23.4 million due to poor sales of its gene-discovery and cloning systems products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more